Strategic and technology alliances enable Genedata to continuously innovate and support emerging experimental technologies. Genedata’s team of dedicated computer and life science experts collaborate with leading organizations to develop and deliver tailored software solutions. Genedata welcomes new opportunities to partner with companies worldwide.

Business Alliances
Developing innovative products through strategic business alliances

AB SCIEX’s global leadership and world-class service and support in the mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide.

Affymetrix technology for analyzing complex genetic information is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes.

ChemAxon is a leader in providing Java based chemical software development platforms for the biotechnology and pharmaceutical industries.

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function.

Ingenuity Systems, a QIAGEN company, is the global leader in applications to quickly analyze and interpret genomic data.

Insilico Biotechnology is a market-leading company providing solutions and software for the simulation of living cells. For world-leading companies from the chemical and pharmaceutical industries, Insilico's technology lowers time, risk and costs of development processes.

IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. Genedata Screener Ready-to-Run partner.

Labcyte Inc. innovations have enabled their customers to enhance personalized medicine programs, streamline DNA/RNA diagnostic testing, optimize drug discovery pipelines and accelerate life science research. Genedata Screener Ready-to-Run partner.

LECO is a leader in innovative analytical instrumentation, mass spectrometers, metallography and optical equipment, and consumables.

PerkinElmer Inc. is a global technology leader driving growth and innovation in health sciences and photonics markets to improve the quality of life.

Thermo Fisher Scientific Inc. is the world leader in serving science with products and services that help accelerate the pace of scientific discovery, and solve a wide range of analytical challenges.

Thomson Reuters (formerly GeneGo) develops systems biology technology such as compound-based pathway analysis, and cheminformatics and bioinformatics software for life science research.

Research Consortia
Contributing to cutting-edge research and development

Toxicology Consortia/Projects

* HeCaToS (FP7) aims at developing integrative in silico tools for predicting human liver and heart toxicity. 

* diXa (FP7) is establishing a data management infrastructure for capturing and integrating all (publicly available) toxicogenomic data sets.

* ExPOsOMICS (FP7) aims to develop a novel approach to the assessment of exposure to high priority environmental pollutants by characterizing the external and the internal components of the exposome.

* ModENP-Tox (FP7) aims to develop a novel and generic “Modeling Assay Platform” (MAP) which can be used as a « Risk Indicator » tool to predict the toxicity of metal-based nano particles (MeNPs).

NTC (Netherlands Toxicogenomics Centre) is using toxigenomics to develop tests that require fewer laboratory animals or cause them less inconvenience, and may eventually replace animal tests completely by in vitro assays using animal or human cells.

PROLIGEN (FP6) consortium studies the regenerative capacity of injured kidneys using information derived from genomics, proteomics, and functional genomics.

InnoMed PredTox (FP6) was aiming at reducing key bottlenecks in the R&D process searching for markers to predict the toxicity of drug candidates.

Oncology Consortia

* EpiFemCare (FP7) is an oncogenomics project to develop a blood based diagnostic test for early detection of breast and ovarian cancer, based on epigenetic markers.

carcinoGENOMICS (FP6) has developed in vitro methods for assessing the carcinogenic potential of compounds.

NewGeneris (FP6) has investigated the role of prenatal and early-life exposure to genotoxic chemicals present in food and the environment in the development of childhood cancer and immune disorders.

INCA (FP6) investigated the role of chronic viral infections in the development of cancer.

Cardiovascular, Diabetes, Nutrition Consortia/Projects

* CVgenes@target (FP7) exploits genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention.

* HUMAN (FP7) aims at the functional validation in animal and cellular models of genetic determinants of diseases and aging processes

* EuRhythDia (FP7) studies chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population.

BioCop (FP6) has been constructed to supply regulators, consumers and industry with long-term solutions to the complex problems associated with chemical contaminant monitoring of foodstuffs.

Other Consortia/Projects

* FUNGITECT is a European consortium dedicated to improving the treatment of invasive fungal diseases via individualized anti-fungal drug therapies. The consortium includes leading academic research institutions, SMEs and industry already successfully positioned in the market.

*GOBI (General Optimization of BIogasprocesses) is an interdisciplinary Biogas research consortium to improve the overall efficiency of biogas production.

* ERANet PathoGenoMics (FP7) is using a systems biology approach to investigate the role of small non-coding RNA (sncRNA) in infectious diseases. ERANet provides novel targets for diagnostics and therapy of the five major high-risk gram-positive human microbial pathogens - Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Listeria.

BaSysBio (FP6), the Bacillus Systems Biology consortium, represents an integrated systems biology project involving 15 research organizations from nine European countries, studying the global regulation of gene transcription in model bacteria.

FRISYS, the Freiburg Initiative for Systems Biology, focuses on modeling and systems analysis of signaling processes in growth and differentiation in human cells and a number of model organisms.

HepatoSys, an interdisciplinary initiative by leading German research centers, aims to understand the physiology and pathophysiology of the human liver cell using a systems biology approach.

Kluyver Centre for Genomics and Industrial Fermentation is a joint industry and academic consortium that applies genomics technology to improve industrial fermentation.

MedSys – “Dr. Jekyll & Mr. Hyde” The German Medical Systems Biology Project (MedSys) is a multidisciplinary project led by leading German research centers to identify novel targets for diagnostics, patient risk assessment, and therapy of infectious disease caused by the opportunistic fungal pathogen Candida albicans.

SysMAP founded and coordinated by the leading specialty chemicals producer Evonik Degussa, the SysMAP consortium exploits novel experimental and computational methods to probe the biological mechanisms underlying industrial fermentation.

* current/ongoing projects